Recent Developments in the Management of Advanced Prostate Cancer

Presenter: Sandy Srinivas
Restricted access

Numerous new options are available for the treatment of prostate cancer when it progresses beyond localized disease. Older drugs, first developed for treatment of metastatic castration-resistant prostate cancer (CRPC), are being used to treat nonmetastatic disease based on results of large randomized controlled trials. Sequencing of available treatment options is challenging for CRPC, but there is some guidance from trial data. Cross-resistance among newer hormonal drugs is a concern, and therefore switching to another class of drug is preferred. Emerging treatments on the horizon, such as PARP inhibitors in patients with BRCA2 mutations and lutetium-177 in those with prostate-specific membrane antigen (PSMA)–positive disease, may look promising to improve outcomes among those with advanced prostate cancer.

Disclosures: Dr. Srinivas has disclosed that she receives grant/research support from Bayer Healthcare, Endocyte, Exelixis Inc., and Genentech, Inc., and that she is a scientific advisor for Bayer Healthcare.

Correspondence: Sandy Srinivas, MD, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305. Email: sandysri@stanford.edu
  • 1.

    Smith MR, Saad F, Chowdhury S, Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:14081418.

  • 2.

    Hussain M, Fizazi K, Saad F, Enzalutamide in men with nonmetastatic castration-resistant prostate cancer. N Engl J Med 2018;378:24652474.

  • 3.

    Fizazi K, Shore N, Tammela TL, Darolutamide in nonmetastatic-castration-resistant prostate cancer. N Engl J Med 2019;380:12351246.

  • 4.

    Sweeney CJ, Chen YH, Carducci M, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737746.

  • 5.

    Gravis G, Fizazi K, Oudard S, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer: a randomized, open-label, phase 3 trial. Lancet Oncol 2013;14:149158.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    James ND, Sydes MR, Clarke NW, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet 2016;387:11631177.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kyriakopoulos CE, Chen YH, Carducci MA, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:10801087.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Fizazi K, Tran N, Fein L, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE) final overall analysis of a randomized, double-blind, phase 3 trial. Lancet Oncol 2019;20:686700.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Armstrong A, Szmulewitz RZ, Petrylak D, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in met with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37:29742986.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Chi KN, Agarwal N, Bjartell A, Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:1324.

  • 11.

    Davis ID, Martin AJ, Stockler MR, Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121131.

  • 12.

    DeWit R, de Bono J, Sternberg CN, Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;38:25062518.

  • 13.

    Hussain M, Mateo J, Fizazi K, PROfound: phase 3 study of olaparib vs. enzalutamide or abiraterone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations [abstract]. Ann Oncol 2019;30(Suppl 5):Abstract LBA_12PR.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Hofman MS, Violet J, Hicks RJ, [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-center, single-arm, phase 2 study. Lancet Oncol 2018;19:825833.

    • Crossref
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 462 462 462
PDF Downloads 142 142 142
EPUB Downloads 0 0 0